US Capitol Capsule: Will pharma get fried in the debt ceiling chicken game?
This article was originally published in Scrip
With the clock ticking ever closer to the 2 August deadline of when the US borrowing authority is set to expire – putting the nation at risk for defaulting on its loans and losing its credit rating – Democratic and Republicans leaders and the White House remained at loggerheads at the end of last week on negotiations over tying a deficit-reduction plan to legislative action to raise the $14.3 trillion debt ceiling.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.